Global Oncology Program, Fred Hutch
Vaccine and Infectious Disease Division, Fred Hutch
Clinical Research Division, Fred Hutch
Dr. Thomas Uldrick is an international expert on HIV-related cancers, especially Kaposi sarcoma and other diseases caused by Kaposi sarcoma herpesvirus. KS remains one of the most common cancers in HIV-infected people worldwide, with a major disease burden in East Africa. One of his key research interests is designing clinical trials, including immunotherapy studies, that accelerate the delivery of the most promising curative cancer therapies to low-income settings. He explores whether a type of immunotherapy known as a checkpoint inhibitor may improve outcomes in patients with both advanced cancers and HIV. By showing that this class of drug is safe in certain cancer patients with HIV, he is helping break down unnecessary barriers to including them in clinical trials.
Associate Professor of Medicine
University of Washington School of Medicine
M.S., Biostatistics, Patient Oriented Research Track, Columbia University, Mailman School of Public Health, 2008
M.D., summa cum laude State University of New York Downstate Medical Center, Brooklyn, NY, 2002
B.A., University of California, Berkeley, 1992
Major research focuses on the pathogenesis and management of viral-associated malignancies, including cancers that occur in the setting of HIV, with specific training in clinical investigation and more than 10 years of clinical trial experience focusing on herpesvirus and related malignancies. This research also explores novel biomarkers in KSHV-associated diseases and HIV viral reservoirs in the setting of cancer. Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity described, KSHV-associated Inflammatory Cytokine Syndrome (KICS), (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating therapies and (3) Evaluation the safety and efficacy of anti-PD-1 therapy in patients with HIV and cancer, which includes evaluation of the effect of anti-PD-1 therapy on HIV reservoirs and HIV-specific immunity. This last study is a multicenter study developed in collaboration with the Cancer Immunotherapy Trials Network and the Delaney AIDS Research Enterprise to Cure HIV. Focusing on disease pathogenesis and development of novel strategies for diagnosis and management of cancers in resource limited settings. This is the focus of research collaborating with investigators in Uganda and South Africa on patient-oriented research projects.